Medication-Induced Osteonecrosis of the Jaw: A Review of Cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)

Ahdi, Hardeep S; Wichelmann, Thomas A.; Pandravada, Sasirekha; Ehrenpreis, Eli D.

doi:10.21203/rs.3.rs-1598822/v1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the limitations of the FAERS database, specifically the absence of denominator data, we cannot directly calculate the incidence of AEs. However, disproportionality analysis serves as a robust method in pharmacovigilance to detect signals of disproportionate reporting related to bendamustine (Ahdi et al, 2023). In our study, we applied both Bayesian and Frequentist approaches to assess the association between bendamustine and AEs.…”

Section: Discussionmentioning

confidence: 99%

Post-marketing risk analysis of bendamustine: a real-world approach based on the FAERS database

Li,

Zhang,

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: Bendamustine was approved for treating chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Despite its therapeutic benefits, the long-term safety of bendamustine in a large population remains inadequately understood. This study evaluates the adverse events (AEs) associated with bendamustine, using a real-world pharmacovigilance database to support its clinical application.Methods: We conducted a post-marketing risk analysis to assess the association between bendamustine and its AEs. Data were extracted from the US FDA’s Adverse Event Reporting System (FAERS), covering the period from January 2017 to September 2023. The characteristics of bendamustine-associated AEs and the onset time were further analyzed. Statistical analysis was performed using MYSQL 8.0, Navicat Premium 15, Microsoft EXCEL 2016, and Minitab 21.0.Results: 9,461,874 reports were collected from the FAERS database, 9,131 identified bendamustine as the “primary suspected” drug. We identified 331 significant disproportionality preferred terms (PTs). Common AEs included pyrexia, neutropenia, infusion site reaction, progressive multifocal leukoencephalopathy (PML), injection site vasculitis, and pneumonia—all documented on bendamustine’s label. Notably, 16 unexpected and significant AEs were discovered, including hypogammaglobulinemia, which is concerning due to its potential to increase infection susceptibility following bendamustine treatment. Other significant findings were anaphylactic reactions, PML, and cutaneous malignancies, suggesting updates to the drug’s label may be necessary. Physicians should monitor for neurological and skin changes in patients and discontinue treatment if PML is suspected. Moreover, the median onset time for bendamustine-associated AEs was 13 days, with an interquartile range [IQR] of 0–59 days, predominantly occurring on the first day post-initiation. The β of bendamustine-related AEs suggested risk reduction over time.Conclusion: Our study uncovered some potential pharmacovigilance signals for bendamustine, providing important insights for its safe and effective clinical use.

show abstract

Section: Discussionmentioning

confidence: 99%